Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Matthew Janowicz

Physician Assistant Myrtle Beach, SC Physician Assistant

NPI 1558735878 CMS profile 11128958

5046 Highway 17 Byp S Ste 103, Myrtle Beach, SC 29588

Open in the dashboard

General payments

$5,945

296 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Janowicz of Myrtle Beach, SC is reported in the CMS Open Payments database as having received $5,945 across 296 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,192 114
2024 General $2,026 109
2023 General $1,391 68
2022 General $231 3
2021 General $105 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Janowicz
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Matthew Janowicz were reported at $2,192. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Matthew Janowicz Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $105 $132 $37–$438 $132
2022 $231 $155 $48–$522 $149
2023 $1,391 $167 $52–$557 $160
2024 $2,026 $178 $55–$600 $164
2025 $2,192 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sun Pharmaceutical Industries Inc. $853 37 payments
  2. Janssen Biotech, Inc. $683 21 payments
  3. AbbVie, Inc. $639 46 payments
  4. Galderma Laboratories, L.P. $442 38 payments
  5. Regeneron Healthcare Solutions, Inc. $394 17 payments
  6. Genzyme Corporation $379 14 payments
  7. Pfizer Inc. $350 17 payments
  8. Incyte Corporation $262 13 payments
  9. UCB, Inc. $261 10 payments
  10. E.R. Squibb & Sons, L.L.C. $259 14 payments
  11. Other $1,422 69 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,115 285 payments
  2. Education $831 11 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $642 19 payments
  2. DUPIXENT $610 22 payments
  3. ILUMYA $507 30 payments
  4. RINVOQ $363 24 payments
  5. CIBINQO $350 17 payments
  6. OPZELURA $262 13 payments
  7. SOTYKTU $259 14 payments
  8. LIBTAYO $230 11 payments
  9. Bimzelx $228 8 payments
  10. SKYRIZI $226 18 payments
  11. Other $3,006 156 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

940

Median for Physician Assistant: 241

Drug cost

$145,299

Median for Physician Assistant: $4,110

Branded share of claims

7.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 33 $122,119
Clobetasol Propionate Generic 122 $4,996
Fluorouracil Generic 44 $2,902
Ketoconazole Generic 151 $2,395
Doxycycline Hyclate Generic 77 $2,233
Metronidazole Generic 35 $1,935
Fluocinonide Generic 47 $1,756
Tacrolimus Generic 17 $1,642
Triamcinolone Acetonide Generic 228 $1,463
Ciclopirox Ciclopirox Olamine Brand 40 $1,391

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$228,866

Of which drugs: $21,198

Medicare patients

1,168

Average age 73

Services billed

6,103

531 women, 637 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 51%
Diabetes 23%
Ischemic heart disease 20%
Chronic kidney disease 16%
Atrial fibrillation 15%
Cancer 15%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 34 89 $69

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $252
$252 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $163
$163 — —
Bimzelx
  • UCB, Inc. $140
$140 — —
OPZELURA
  • Incyte Corporation $137
$137 — —
CIBINQO
  • PFIZER INC. $135
$135 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

296 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record